This article was originally published on MedTech Intelligence. With the COVID-19 pandemic shuttering physician offices and walk-in clinics, patients and doctors across Asian markets have turned increasingly to telehealth solutions. The surge is creating a short-term boom—and the likelihood of a long-term... Read More
https://attendee.gotowebinar.com/recording/5890292005019691021 Read More
Changes to pharmaceutical registration regulations in China that go into effect on July 1 are designed to bolster safety requirements for clinical trials, encourage the development of generic drugs, limit fraud in clinical data and expedite the pharmaceutical approval process. For example,... Read More
If a foreign medical device company does not have its own office in China and does not want to let their distributor register their product there, registration can be done by an independent third-party company (agent) located in China. In all three cases,... Read More
As part of its continuing effort to align its regulatory approach to drug registration and regulation with international practices, China is proposing modifications to the way it categorizes pharmaceuticals. The draft plans would be the first restructuring of registration classifications of chemical... Read More
Spurred by the coronavirus crisis, China is moving for the first time to permit first-time medical diagnoses to be conducted online. The move by China’s National Development and Reform Commission (NDRC) is part of a major new push to move many healthcare... Read More
China’s punishing experience with COVID-19 is likely to push forward deep reforms already underway in the nation’s healthcare system, shifting medical diagnosis and treatment away from large hospitals, furthering digitalization and telehealth, etc. That is the conclusion of a new report by... Read More
This article was originally published on MedTech Intelligence. Led by Chinese Internet commerce giants Tencent and Alibaba, internet providers have been offering a vast array of cloud computing services free to researchers and clinicians, while hiking their investment in advanced technologies, since... Read More
This article was originally published on FDLI. Introduction China’s drug market has exploded over the last few years, and future growth is estimated at 6-7% over the next five years. Valued at about $140 billion, it is now the second-largest drug market... Read More
Moving to better ensure the safety of medical devices available in China, the National Medical Products Administration (NMPA) in April announced it will implement random inspection regimens on the manufacture, management, distribution, and delivery of such devices already on the market. Under... Read More